Statistics photos on Flickr

View allAll Photos Tagged Statistics

Important Statistics by John C Bullas BSc MSc PhD MCIHT MIAT

2 1

Important Statistics funny ones

The education subdivision is responsible for a territory with a population of 150.000. This is their statistics department.

Twitter Infographics by Katie

Some fun Twitter statistics such as the % of people who don't know what a # is, when the first tweet was sent from space and the most Tweets Per Second.

Photo Source:

www.bitrebels.com/social/twitterpalooza-twitter-statistic...

World leader, scientist, medical scientist, virologist, pharmacist, Professor Fangruida (F.D Smith) on the world epidemic and the nemesis and prevention of new coronaviruses and mutant viruses (Jacques Lucy) 2021v1.5) by rs Vots

_-----------------------------------------

The Nemesis and Killer of New Coronavirus and Mutated Viruses-Joint Development of Vaccines and Drugs (Fangruida) July 2021

*The particularity of new coronaviruses and mutant viruses*The broad spectrum, high efficiency, redundancy, and safety of the new coronavirus vaccine design and development , Redundancy and safety

*New coronavirus drug chemical structure modification*Computer-aided design and drug screening. *"Antiviral biological missile", "New Coronavirus Anti-epidemic Tablets", "Composite Antiviral Oral Liquid", "New Coronavirus Long-acting Oral Tablets", "New Coronavirus Inhibitors" (injection)

——————————————————————————

(World leader, scientist, medical scientist, biologist, virologist, pharmacist, FD Smith) "The Nemesis and Killer of New Coronavirus and Mutated Viruses-The Joint Development of Vaccines and Drugs" is an important scientific research document. Now it has been revised and re-published by the original author several times. The compilation is published and published according to the original manuscript to meet the needs of readers and netizens all over the world. At the same time, it is also of great benefit to the vast number of medical clinical drug researchers and various experts and scholars. We hope that it will be corrected in the reprint.------Compiled by Jacques Lucy in Geneva, August 2021

-------------------------------------------------- ---------------------

According to Worldometer's real-time statistics, as of about 6:30 on July 23, there were a total of 193,323,815 confirmed cases of new coronary pneumonia worldwide, and a total of 4,150,213 deaths. There were 570,902 new confirmed cases and 8,766 new deaths worldwide in a single day. Data shows that the United States, Brazil, the United Kingdom, India, and Indonesia are the five countries with the largest number of new confirmed cases, and Indonesia, Brazil, Russia, South Africa, and India are the five countries with the largest number of new deaths.

The new coronavirus and delta mutant strains have been particularly serious in the recent past. Many countries and places have revived, and the number of cases has not decreased, but has increased.

, It is worthy of vigilance. Although many countries have strengthened vaccine prevention and control and other prevention and control measures, there are still many shortcomings and deficiencies in virus suppression and prevention. The new coronavirus and various mutant strains have a certain degree of antagonism to traditional drugs and most vaccines. Although most vaccines have great anti-epidemic properties and have important and irreplaceable effects and protection for prevention and treatment, it is impossible to completely prevent the spread and infection of viruses. The spread of the new crown virus pneumonia has been delayed for nearly two years. There are hundreds of millions of people infected worldwide, millions of deaths, and the time is long, the spread is widespread, and billions of people around the world are among them. The harm of the virus is quite terrible. This is well known. of. More urgent

What is more serious is that the virus and mutant strains have not completely retreated, especially many people are still infected and infected after being injected with various vaccines. The effectiveness of the vaccine and the resistance of the mutant virus are worthy of medical scientists, virologists, pharmacologists Zoologists and others seriously think and analyze. The current epidemic situation in European and American countries, China, Brazil, India, the United States, Russia and other countries has greatly improved from last year. However, relevant figures show that the global epidemic situation has not completely improved, and some countries and regions are still very serious. In particular, after extensive use of various vaccines, cases still occur, and in some places they are still very serious, which deserves a high degree of vigilance. Prevention and control measures are very important. In addition, vaccines and various anti-epidemic drugs are the first and necessary choices, and other methods are irreplaceable. It is particularly important to develop and develop comprehensive drugs, antiviral drugs, immune drugs, and genetic drugs. Research experiments on new coronaviruses and mutant viruses require more rigorous and in-depth data analysis, pathological pathogenic tissues, cell genes, molecular chemistry, quantum chemistry, etc., as well as vaccine molecular chemistry, quantum physics, quantum biology, cytological histology, medicinal chemistry, and drugs And the vaccine’s symptomatic, effectiveness, safety, long-term effectiveness, etc., of course, including tens of thousands of clinical cases and deaths and other first-hand information and evidence. The task of RNA (ribonucleic acid) in the human body is to use the information of our genetic material DNA to produce protein. It accomplishes this task in the ribosome, the protein-producing area of the cell. The ribosome is the place where protein biosynthesis occurs.

Medicine takes advantage of this: In vaccination, artificially produced mRNA provides ribosomes with instructions for constructing pathogen antigens to fight against—for example, the spike protein of coronavirus.

Traditional live vaccines or inactivated vaccines contain antigens that cause the immune system to react. The mRNA vaccine is produced in the cell

(1) The specificity of new coronaviruses and mutant viruses, etc., virology and quantum chemistry of mutant viruses, quantum physics, quantum microbiology

(2) New crown vaccine design, molecular biology and chemical structure, etc.

(3) The generality and particularity of the development of new coronavirus drugs

(4) Various drug design for new coronavirus pneumonia, medicinal chemistry, pharmacology, etc., cells, proteins, DNA, enzyme chemistry, pharmaceutical quantum chemistry, pharmaceutical quantum physics, human biochemistry, human biophysics, etc.

(5) The evolution and mutation characteristics of the new coronavirus and various mutant viruses, the long-term nature, repeatability, drug resistance, and epidemic resistance of the virus, etc.

(6) New coronavirus pneumonia and the infectious transmission of various new coronaviruses and their particularities

(7) The invisible transmission of new coronavirus pneumonia and various mutant viruses in humans or animals, and the mutual symbiosis of cross infection of various bacteria and viruses are also one of the very serious causes of serious harm to new coronaviruses and mutant viruses. Virology, pathology, etiology, gene sequencing, gene mapping, and a large number of analytical studies have shown that there are many cases in China, the United States, India, Russia, Brazil, and other countries.

(8) For the symptomatic prevention and treatment of the new coronavirus, the combination of various vaccines and various antiviral drugs is critical.

(9) According to the current epidemic situation and research judgments, the epidemic situation may improve in the next period of time and 2021-2022, and we are optimistic about its success. However, completely worry-free, it is still too early to win easily. It is not just relying on vaccination. Wearing masks to close the city and other prevention and control measures and methods can sit back and relax, and you can win a big victory. Because all kinds of research and exploration still require a lot of time and various experimental studies. It is not a day's work. A simple taste is very dangerous and harmful. The power and migratory explosiveness of viruses sometimes far exceed human thinking and perception. In the future, next year, or in the future, whether viruses and various evolutionary mutation viruses will re-attack, we still need to study, analyze, prevent and control, rather than being complacent, thinking that the vaccine can win a big victory is inevitably naive and ridiculous. Vaccine protection is very important, but it must not be taken carelessly. The mutation of the new crown virus is very rampant, and the cross-infection of recessive and virulent bacteria makes epidemic prevention and anti-epidemic very complicated.

(10) New crown virus pneumonia and the virus's stubbornness, strength, migration, susceptibility, multi-infectiousness, and occult. The effectiveness of various vaccines and the particularity of virus mutations The long-term hidden dangers and repeated recurrences of the new coronavirus

(11) The formation mechanism and invisible transmission of invisible viruses, asymptomatic infections and asymptomatic infections, asymptomatic transmission routes, asymptomatic infections, pathological pathogens. The spread and infection of viruses and mutated viruses, the blind spots and blind spots of virus vaccines, viral quantum chemistry and

The chemical and physical corresponding reactions at the meeting points of highly effective vaccine drugs, etc. The variability of mutated viruses is very complicated, and vaccination cannot completely prevent the spread of infection.

(12) New crown virus pneumonia and various respiratory infectious diseases are susceptible to infections in animals and humans, and are frequently recurring. This is one of the frequently-occurring and difficult diseases of common infectious diseases. Even with various vaccines and various antiviral immune drugs, it is difficult to completely prevent the occurrence and spread of viral pneumonia. Therefore, epidemic prevention and anti-epidemic is a major issue facing human society, and no country should take it lightly. The various costs that humans pay on this issue are very expensive, such as Ebola virus, influenza A virus,

Hepatitis virus,

Marburg virus

Sars coronavirus, plague, anthracnose, cholera

and many more. The B.1.1.7 mutant virus that was first discovered in the UK was renamed Alpha mutant virus; the B.1.351 that was first discovered in South Africa was renamed Beta mutant virus; the P.1 that was first discovered in Brazil was renamed Gamma mutant virus; the mutation was first discovered in India There are two branches of the virus. B.1.617.2, which was listed as "mutated virus of concern", was renamed Delta mutant virus, and B.1.617.1 of "mutated virus to be observed" was renamed Kappa mutant virus.

However, experts in many countries believe that the current vaccination is still effective, at least it can prevent severe illness and reduce deaths.

　　　　 Delta mutant strain

According to the degree of risk, the WHO divides the new crown variant strains into two categories: worrying variant strains (VOC, variant of concern) and noteworthy variant strains (VOI, variant of interest). The former has caused many cases and a wide range of cases worldwide, and data confirms its transmission ability, strong toxicity, high power, complex migration, and high insidious transmission of infection. Resistance to vaccines may lead to the effectiveness of vaccines and clinical treatments. Decrease; the latter has confirmed cases of community transmission worldwide, or has been found in multiple countries, but has not yet formed a large-scale infection. Need to be very vigilant. Various cases and deaths in many countries in the world are related to this. In some countries, the epidemic situation is repeated, and it is also caused by various reasons and viruses, of course, including new cases and so on.

At present, VOC is the mutant strain that has the greatest impact on the epidemic and the greatest threat to the world, including: Alpha, Beta, Gamma and Delta. , Will the change of the spur protein in the VOC affect the immune protection effect of the existing vaccine, or whether it will affect the sensitivity of the VOC to the existing vaccine? For this problem, it is necessary to directly test neutralizing antibodies, such as those that can prevent the protection of infection. Antibodies recognize specific protein sequences on viral particles, especially those spike protein sequences used in mRNA vaccines.

(13) Countries around the world, especially countries and regions with more severe epidemics, have a large number of clinical cases, severe cases, and deaths, especially including many young and middle-aged patients, including those who have been vaccinated. The epidemic is more complicated and serious. Injecting various vaccines, taking strict control measures such as closing the city and wearing masks are very important and the effect is very obvious. However, the new coronavirus and mutant viruses are so repeated, their pathological pathogen research will also be very complicated and difficult. After the large-scale use of the vaccine, many people are still infected. In addition to the lack of prevention and control measures, it is very important that the viability of the new coronavirus and various mutant viruses is very important. It can escape the inactivation of the vaccine. It is very resistant to stubbornness. Therefore, the recurrence of new coronavirus pneumonia is very dangerous. What is more noteworthy is that medical scientists, virologists, pharmacists, biologists, zoologists and clinicians should seriously consider the correspondence between virus specificity and vaccine drugs, and the coupling of commonality and specificity. Only in this way can we find targets. Track and kill viruses. Only in this sense can the new crown virus produce a nemesis, put an end to and eradicate the new crown virus pneumonia. Of course, this is not a temporary battle, but a certain amount of time and process to achieve the goal in the end.

(14) The development and evolution of the natural universe and earth species, as well as life species. With the continuous evolution of human cell genes, microbes and bacterial viruses are constantly mutated and inherited. The new world will inevitably produce a variety of new pathogens.

And viruses. For example, neurological genetic disease, digestive system disease, respiratory system disease, blood system disease, cardiopulmonary system disease, etc., new diseases will continue to emerge as humans develop and evolve. Human migration to space, space diseases, space psychological diseases, space cell diseases, space genetic diseases, etc. Therefore, for the new coronavirus and mutated viruses, we must have sufficient knowledge and response, and do not think that it will be completely wiped out.

, And is not a scientific attitude. Viruses and humans mutually reinforce each other, and viruses and animals and plants mutually reinforce each other. This is the iron law of the natural universe. Human beings can only adapt to natural history, but cannot deliberately modify natural history.

Active immune products made from specific bacteria, viruses, rickettsiae, spirochetes, mycoplasma and other microorganisms and parasites are collectively called vaccines. Vaccination of animals can make the animal body have specific immunity. The principle of vaccines is to artificially attenuate, inactivate, and genetically attenuate pathogenic microorganisms (such as bacteria, viruses, rickettsia, etc.) and their metabolites. Purification and preparation methods, made into immune preparations for the prevention of infectious diseases. In terms of ingredients, the vaccine retains the antigenic properties and other characteristics of the pathogen, which can stimulate the body's immune response and produce protective antibodies. But it has no pathogenicity and does not cause harm to the body. When the body is exposed to this pathogen again, the immune system will produce more antibodies according to the previous memory to prevent the pathogen from invading or to fight against the damage to the body. (1) Inactivated vaccines: select pathogenic microorganisms with strong immunogenicity, culture them, inactivate them by physical or chemical methods, and then purify and prepare them. The virus species used in inactivated vaccines are generally virulent strains, but the use of attenuated attenuated strains also has good immunogenicity, such as the inactivated polio vaccine produced by the Sabin attenuated strain. The inactivated vaccine has lost its infectivity to the body, but still maintains its immunogenicity, which can stimulate the body to produce corresponding immunity and resist the infection of wild strains. Inactivated vaccines have a good immune effect. They can generally be stored for more than one year at 2～8°C without the risk of reversion of virulence; however, the inactivated vaccines cannot grow and reproduce after entering the human body. They stimulate the human body for a short time and must be strong and long-lasting. In general, adjuvants are required for immunity, and multiple injections in large doses are required, and the local immune protection of natural infection is lacking. Including bacteria, viruses, rickettsiae and toxoid preparations.

(2) Live attenuated vaccine: It is a vaccine made by using artificial targeted mutation methods or by screening live microorganisms with highly weakened or basically non-toxic virulence from the natural world. After inoculation, the live attenuated vaccine has a certain ability to grow and reproduce in the body, which can cause the body to have a reaction similar to a recessive infection or a mild infection, and it is widely used.

(3) Subunit vaccine: Among the multiple specific antigenic determinants carried by macromolecular antigens, only a small number of antigenic sites play an important role in the protective immune response. Separate natural proteins through chemical decomposition or controlled proteolysis, and extract bacteria and virusesVaccines made from fragments with immunological activity are screened out of the special protein structure of, called subunit vaccines. Subunit vaccines have only a few major surface proteins, so they can eliminate antibodies induced by many unrelated antigens, thereby reducing the side effects of the vaccine and related diseases and other side effects caused by the vaccine. (4) Genetically engineered vaccine: It uses DNA recombination biotechnology to direct the natural or synthetic genetic material in the pathogen coat protein that can induce the body's immune response into bacteria, yeast or mammalian cells to make it fully expressed. A vaccine prepared after purification. The application of genetic engineering technology can produce subunit vaccines that do not contain infectious substances, stable attenuated vaccines with live viruses as carriers, and multivalent vaccines that can prevent multiple diseases. This is the second-generation vaccine following the first-generation traditional vaccine. It has the advantages of safety, effectiveness, long-term immune response, and easy realization of combined immunization. It has certain advantages and effects.

New coronavirus drug development, drug targets and chemical modification.

Ligand-based drug design (or indirect drug design planning) relies on the knowledge of other molecules that bind to the target biological target. These other molecules can be used to derive pharmacophore models and structural modalities, which define the minimum necessary structural features that the molecule must have in order to bind to the target. In other words, a model of a biological target can be established based on the knowledge of the binding target, and the model can be used to design new molecular entities and other parts that interact with the target. Among them, the quantitative structure-activity relationship (QSAR) is included, in which the correlation between the calculated properties of the molecule and its experimentally determined biological activity can be derived. These QSAR relationships can be used to predict the activity of new analogs. The structure-activity relationship is very complicated.

Based on structure

Structure-based drug design relies on knowledge of the three-dimensional structure of biological targets obtained by methods such as X-ray crystallography or NMR spectroscopy and quantum chemistry. If the experimental structure of the target is not available, it is possible to create a homology model of the target and other standard models that can be compared based on the experimental structure of the relevant protein. Using the structure of biological targets, interactive graphics and medical chemists’ intuitive design can be used to predict drug candidates with high affinity and selective binding to the target. Various automatic calculation programs can also be used to suggest new drug candidates.

The current structure-based drug design methods can be roughly divided into three categories. The 3D method is to search a large database of small molecule 3D structures to find new ligands for a given receptor, in order to use a rapid approximate docking procedure to find those suitable for the receptor binding pocket. This method is called virtual screening. The second category is the de novo design of new ligands. In this method, by gradually assembling small fragments, a ligand molecule is established within the constraints of the binding pocket. These fragments can be single atoms or molecular fragments. The main advantage of this method is that it can propose novel structures that are not found in any database. The third method is to optimize the known ligand acquisition by evaluating the proposed analogs in the binding cavity.

Bind site ID

Binding site recognition is a step in structure-based design. If the structure of the target or a sufficiently similar homologue is determined in the presence of the bound ligand, the ligand should be observable in that structure, in which case the location of the binding site is small. However, there may not be an allosteric binding site of interest. In addition, only apo protein structures may be available, and it is not easy to reliably identify unoccupied sites that have the potential to bind ligands with high affinity. In short, the recognition of binding sites usually depends on the recognition of pits. The protein on the protein surface can hold molecules the size of drugs, etc. These molecules also have appropriate "hot spots" that drive ligand binding, hydrophobic surfaces, hydrogen bonding sites, and so on.

Drug design is a creative process of finding new drugs based on the knowledge of biological targets. The most common type of drug is small organic molecules that activate or inhibit the function of biomolecules, thereby producing therapeutic benefits for patients. In the most important sense, drug design involves the design of molecules with complementary shapes and charges that bind to their interacting biomolecular targets, and therefore will bind to them. Drug design often but does not necessarily rely on computer modeling techniques. A more accurate term is ligand design. Although the design technology for predicting binding affinity is quite successful, there are many other characteristics, such as bioavailability, metabolic half-life, side effects, etc., which must be optimized first before the ligand can become safe and effective. drug. These other features are usually difficult to predict and realize through reasonable design techniques. However, due to the high turnover rate, especially in the clinical stage of drug development, in the early stage of the drug design process, more attention is paid to the selection of drug candidates. The physical and chemical properties of these drug candidates are expected to be reduced during the development process. Complications are therefore more likely to lead to the approval of the marketed drug. In addition, in early drug discovery, in vitro experiments with computational methods are increasingly used to select compounds with more favorable ADME (absorption, distribution, metabolism, and excretion) and toxicological characteristics. A more accurate term is ligand design. Although the design technique for predicting binding affinity is quite successful, there are many other characteristics, such as bioavailability, metabolic half-life, side effects, iatrogenic effects, etc., which must be optimized first, and then the ligand To become safe and effective.

For drug targets, two aspects should be considered when selecting drug targets:

1. The effectiveness of the target, that is, the target is indeed related to the disease, and the symptoms of the disease can be effectively improved by regulating the physiological activity of the target.

2. The side effects of the target. If the regulation of the physiological activity of the target inevitably produces serious side effects, it is inappropriate to select it as the target of drug action or lose its important biological activity. The reference frame of the target should be expanded in multiple dimensions to have a big choice.

3. Search for biomolecular clues related to diseases: use genomics, proteomics and biochip technology to obtain biomolecular information related to diseases, and perform bioinformatics analysis to obtain clue information.

4. Perform functional research on related biomolecules to determine the target of candidate drugs. Multiple targets or individual targets.

5. Candidate drug targets, design small molecule compounds, and conduct pharmacological research at the molecular, cellular and overall animal levels.

Covalent bonding type

The covalent bonding type is an irreversible form of bonding, similar to the organic synthesis reaction that occurs. Covalent bonding types mostly occur in the mechanism of action of chemotherapeutic drugs. For example, alkylating agent anti-tumor drugs produce covalent bonding bonds to guanine bases in DNA, resulting in cytotoxic activity.

. Verify the effectiveness of the target.

Based on the targets that interact with drugs, that is, receptors in a broad sense, such as enzymes, receptors, ion channels, membranes, antigens, viruses, nucleic acids, polysaccharides, proteins, enzymes, etc., find and design reasonable drug molecules. Targets of action and drug screening should focus on multiple points. Drug intermediates and chemical modification. Combining the development of new drugs with the chemical structure modification of traditional drugs makes it easier to find breakthroughs and develop new antiviral drugs. For example, careful selection, modification and modification of existing related drugs that can successfully treat and recover a large number of cases, elimination and screening of invalid drugs from severe death cases, etc., are targeted, rather than screening and capturing needles in a haystack, aimless, with half the effort. Vaccine design should also be multi-pronged and focused. The broad-spectrum, long-term, safety, efficiency and redundancy of the vaccine should all be considered. In this way, it will be more powerful to deal with the mutation and evolution of the virus. Of course, series of vaccines, series of drugs, second-generation vaccines, third-generation vaccines, second-generation drugs, third-generation drugs, etc. can also be developed. Vaccines focus on epidemic prevention, and medicines focus on medical treatment. The two are very different; however, the two complement each other and complement each other. Therefore, in response to large-scale epidemics of infectious diseases, vaccines and various drugs are the nemesis and killers of viral diseases. Of course, it also includes other methods and measures, so I won't repeat them here.

Mainly through the comprehensive and accurate understanding of the structure of the drug and the receptor at the molecular level and even the electronic level, structure-based drug design and the understanding of the structure, function, and drug action mode of the target and the mechanism of physiological activity Mechanism-based drug design.

Compared with the traditional extensive pharmacological screening and lead compound optimization, it has obvious advantages.

Viral RNA replicase, also known as RNA-dependent RNA polymerase (RdRp) is responsible for the replication and transcription of RNA virus genome, and plays a very important role in the process of virus self-replication in host cells, and It also has a major impact on the mutation of the virus, it will change and accelerate the replication and recombination. Because RdRp from different viruses has a highly conserved core structure, the virus replicase is an important antiviral drug target and there are other selection sites, rather than a single isolated target target such as the new coronavirus As with various mutant viruses, inhibitors developed for viral replicase are expected to become a broad-spectrum antiviral drug. The currently well-known anti-coronavirus drug remdesivir (remdesivir) is a drug for viral replicase.

New antiviral therapies are gradually emerging. In addition to traditional polymerase and protease inhibitors, nucleic acid drugs, cell entry inhibitors, nucleocapsid inhibitors, and drugs targeting host cells are also increasingly appearing in the research and development of major pharmaceutical companies. The treatment of mutated viruses is becoming increasingly urgent. The development of drugs for the new coronavirus pneumonia is very important. It is not only for the current global new coronavirus epidemic, but more importantly, it is of great significance to face the severe pneumonia-respiratory infectious disease that poses a huge threat to humans.

There are many vaccines and related drugs developed for the new coronavirus pneumonia, and countries are vying for a while, mainly including the following:

Identification test, appearance, difference in loading, moisture, pH value, osmolality, polysaccharide content, free polysaccharide content, potency test, sterility test, pyrogen test, bacterial endotoxin test, abnormal toxicity test.

Among them: such as sterility inspection, pyrogen inspection, bacterial endotoxin, and abnormal toxicity inspection are indicators closely related to safety.

Polysaccharide content, free polysaccharide content, and efficacy test are indicators closely related to vaccine effectiveness.

Usually, a vaccine will go through a long research and development process of at least 8 years or even more than 20 years from research and development to marketing. The outbreak of the new crown epidemic requires no delay, and the design and development of vaccines is speeding up. It is not surprising in this special period. Of course, it is understandable that vaccine design, development and testing can be accelerated, shortened the cycle, and reduced some procedures. However, science needs to be rigorous and rigorous to achieve great results. The safety and effectiveness of vaccines are of the utmost importance. There must not be a single error. Otherwise, it will be counterproductive and need to be continuously improved and perfected.

Pre-clinical research: The screening of strains and cells is the basic guarantee to ensure the safety, effectiveness, and continuous supply of vaccines. Taking virus vaccines as an example, the laboratory stage needs to carry out strain screening, necessary strain attenuation, strain adaptation to the cultured cell matrix and stability studies in the process of passaging, and explore the stability of process quality, establish animal models, etc. . Choose mice, guinea pigs, rabbits or monkeys for animal experiments according to each vaccine situation. Pre-clinical research generally takes 5-10 years or longer on the premise that the process is controllable, the quality is stable, and it is safe and effective. In order to be safe and effective, a certain redundant design is also needed, so that the safety and effectiveness of the vaccine can be importantly guaranteed.

These include the establishment of vaccine strain/cell seed bank, production process research, quality research, stability research, animal safety evaluation and effectiveness evaluation, and clinical trial programs, etc.

The ARS-CoV-2 genome contains at least 10 ORFs. ORF1ab is converted into a polyprotein and processed into 16 non-structural proteins (NSP). These NSPs have a variety of functional biological activities, physical and chemical reactions, such as genome replication, induction of host mRNA cleavage, membrane rearrangement, autophagosome production, NSP polyprotein cleavage, capping, tailing, methylation, RNA double-stranded Uncoiling, etc., and others, play an important role in the virus life cycle. In addition, SARS-CoV-2 contains 4 structural proteins, namely spike (S), nucleocapsid (N), envelope (E) and membrane (M), all of which are encoded by the 3'end of the viral genome. Among the four structural proteins, S protein is a large multifunctional transmembrane protein that plays an important role in the process of virus adsorption, fusion, and injection into host cells, and requires in-depth observation and research.

1S protein is composed of S1 and S2 subunits, and each subunit can be further divided into different functional domains. The S1 subunit has 2 domains: NTD and RBD, and RBD contains conservative RBM. The S2 subunit has 3 structural domains: FP, HR1 and HR2. The S1 subunit is arranged at the top of the S2 subunit to form an immunodominant S protein.

The virus uses the host transmembrane protease Serine 2 (TMPRSS2) and the endosomal cysteine protease CatB/L to enter the cell. TMPRSS2 is responsible for the cleavage of the S protein to expose the FP region of the S2 subunit, which is responsible for initiating endosome-mediated host cell entry into it. It shows that TMPRSS2 is a host factor necessary for virus entry. Therefore, the use of drugs that inhibit this protease can achieve the purpose of treatment.

mRNA-1273

The mRNA encoding the full length of SARS-CoV-2, and the pre-spike protein fusion is encapsulated into lipid nanoparticles to form mRNA-1273 vaccine. It can induce a high level of S protein specific antiviral response. It can also consist of inactivated antigens or subunit antigens. The vaccine was quickly approved by the FDA and has entered phase II clinical trials. The company has announced the antibody data of 8 subjects who received different immunization doses. The 25ug dose group achieved an effect similar to the antibody level during the recovery period. The 100ug dose group exceeded the antibody level during the recovery period. In the 25ug and 100ug dose groups, the vaccine was basically safe and tolerable, while the 250ug dose group had 3 levels of systemic symptoms.

Viral vector vaccines can provide long-term high-level expression of antigen proteins, induce CTLs, and ultimately eliminate viral infections.

1, Ad5-nCov

A vaccine of SARS-CoV-2 recombinant spike protein expressed by recombinant, replication-deficient type 5 adenovirus (Ad5) vector. Load the optimized full-length S protein gene together with the plasminogen activation signal peptide gene into the E1 and E3 deleted Ad5 vectors. The vaccine is constructed by the Admax system derived from Microbix Biosystem. In phase I clinical trials, RBD (S1 subunit receptor binding domain) and S protein neutralizing antibody increased by 4 times 14 days after immunization, reaching a peak on 28 days. CD4+T and CD8+T cells reached a peak 14 days after immunization. The existing Ad5 immune resistance partially limits the response of antibodies and T cells. This study will be further conducted in the 18-60 age group, receiving 1/3 of the study dose, and follow-up for 3-6 months after immunization.

DNA vaccine

The introduction of antigen-encoding DNA and adjuvants as vaccines is the most innovative vaccine method. The transfected cells stably express the transgenic protein, similar to live viruses. The antigen will be endocytosed by immature DC, and finally provide antigen to CD4 + T, CD8 + T cells (by MHC differentiation) To induce humoral and cellular immunity. Some specificities of the virus and the new coronavirus mutant are different from general vaccines and other vaccines. Therefore, it is worth noting the gene expression of the vaccine. Otherwise, the effectiveness and efficiency of the vaccine will be questioned.

Live attenuated vaccine

DelNS1-SARS-CoV2-RBD

Basic influenza vaccine, delete NS1 gene. Express SARS-CoV-2 RBD domain. Cultured in CEF and MDCK (canine kidney cells) cells. It is more immunogenic than wild-type influenza virus and can be administered by nasal spray.

The viral genome is susceptible to mutation, antigen transfer and drift can occur, and spread among the population. Mutations can vary depending on the environmental conditions and population density of the geographic area. After screening and comparing 7,500 samples of infected patients, scientists found 198 mutations, indicating the evolutionary mutation of the virus in the human host. These mutations may form different virus subtypes, which means that even after vaccine immunization, viral infections may occur. A certain amount of increment and strengthening is needed here.

Inactivated vaccines, adenovirus vector vaccines, recombinant protein vaccines, nucleic acid vaccines, attenuated influenza virus vector vaccines, etc. According to relevant information, there are dozens of new coronavirus vaccines in the world, and more varieties are being developed and upgraded. Including the United States, Britain, China, Russia, India and other countries, there are more R&D and production units.

AZ vaccine

Modena vaccine

Lianya Vaccine

High-end vaccine

Pfizer vaccine

Pfizer-BioNTech

A large study found that the vaccine developed by Pfizer and German biotechnology company BioNTech is 95% effective in preventing COVID-19.

The vaccine is divided into two doses, which are injected every three weeks.

This vaccine uses a molecule called mRNA as its basis. mRNA is a molecular cousin of DNA, which contains instructions to build specific proteins; in this case, the mRNA in the vaccine encodes the coronavirus spike protein, which is attached to the surface of the virus and used to infect human cells. Once the vaccine enters the human body, it will instruct the body's cells to make this protein, and the immune system will learn to recognize and attack it.

Moderna

The vaccine developed by the American biotechnology company Moderna and the National Institute of Allergy and Infectious Diseases (NIAID) is also based on mRNA and is estimated to be 94.5% effective in preventing COVID-19.

Like Pfizer's vaccine, this vaccine is divided into two doses, but injected every four weeks instead of three weeks. Another difference is that the Moderna vaccine can be stored at minus 20 degrees Celsius instead of deep freezing like Pfizer vaccine. At present, the importance of one of the widely used vaccines is self-evident.

Oxford-AstraZeneca

The vaccine developed by the University of Oxford and the pharmaceutical company AstraZeneca is approximately 70% effective in preventing COVID-19-that is, in clinical trials, adjusting the dose seems to improve this effect.

In the population who received two high-dose vaccines (28 days apart), the effectiveness of the vaccine was about 62%; according to early analysis, the effectiveness of the vaccine in those patients who received the half-dose first and then the full-dose Is 90%. However, in clinical trials, participants taking half doses of the drug are wrong, and some scientists question whether these early results are representative.

Sinopharm Group (Beijing Institute of Biological Products, China)

China National Pharmaceutical Group Sinopharm and Beijing Institute of Biological Products have developed a vaccine from inactivated coronavirus (SARS-CoV-2). The inactivated coronavirus is an improved version that cannot be replicated.

Estimates of the effectiveness of vaccines against COVID-19 vary.

Gamaleya Institute

The Gamaleya Institute of the Russian Ministry of Health has developed a coronavirus vaccine candidate called Sputnik V. This vaccine contains two common cold viruses, adenoviruses, which have been modified so that they will not replicate in the human body; the modified virus also contains a gene encoding the coronavirus spike protein.

New crown drugs

There are many small molecule antiviral drug candidates in the clinical research stage around the world. Including traditional drugs in the past and various drugs yet to be developed, antiviral drugs, immune drugs, Gene drugs, compound drugs, etc.

(A) Molnupiravir

Molnupiravir is a prodrug of the nucleoside analog N4-hydroxycytidine (NHC), jointly developed by Merck and Ridgeback Biotherapeutics.

The positive rate of infectious virus isolation and culture in nasopharyngeal swabs was 0% (0/47), while that of patients in the placebo group was 24% (6/25). However, data from the Phase II/III study indicate that the drug has no benefit in preventing death or shortening the length of stay in hospitalized patients.

Therefore, Merck has decided to fully advance the research of 800mg molnupiravir in the treatment of patients with mild to moderate COVID-19.

(B) AT-527

AT-527 is a small molecule inhibitor of viral RNA polymerase, jointly developed by Roche and Atea. Not only can it be used as an oral therapy to treat hospitalized COVID-19 patients, but it also has the potential as a preventive treatment after exposure.

Including 70 high-risk COVID-19 hospitalized patients data, of which 62 patients' data can be used for virological analysis and evaluation. The results of interim virological analysis show that AT-527 can quickly reduce viral load. On day 2, compared with placebo, patients treated with AT-527 had a greater decline in viral load than the baseline level, and the continuous difference in viral load decline was maintained until day 8.

In addition, compared with the control group, the potent antiviral activity of AT-527 was also observed in patients with a baseline median viral load higher than 5.26 log10. When testing by RT-qPCR to assess whether the virus is cleared,

The safety aspect is consistent with previous studies. AT-527 showed good safety and tolerability, and no new safety problems or risks were found. Of course, there is still a considerable distance between experiment and clinical application, and a large amount of experimental data can prove it.

Prokalamide is an AR (androgen receptor) antagonist. Activated androgen receptor AR can induce the expression of transmembrane serine protease (TMPRSS2). TMPRSS2 has a shearing effect on the new coronavirus S protein and ACE2, which can promote the binding of viral spike protein (S protein) to ACE, thereby promoting The virus enters the host cell. Therefore, inhibiting the androgen receptor may inhibit the viral infection process, and AR antagonists are expected to become anti-coronavirus drugs.

Positive results were obtained in a randomized, double-blind, placebo-controlled phase III clinical trial. The data shows that Prokalutamide reduces the risk of death in severely ill patients with new coronary disease by 92%, reduces the risk of new ventilator use by 92%, and shortens the length of hospital stay by 9 days. This shows that procrulamide has a certain therapeutic effect for patients with severe new coronary disease, which can significantly reduce the mortality of patients, and at the same time greatly reduce the new mechanical ventilation and shorten the patient's hospital stay.

With the continuous development of COVID-19 on a global scale, in addition to vaccines and prevention and control measures, we need a multi-pronged plan to control this disease. Oral antiviral therapy undoubtedly provides a convenient treatment option.

In addition, there are other drugs under development and experimentation. In dealing with the plague virus, in addition to the strict control of protective measures, it is very important that various efficient and safe vaccines and various drugs (including medical instruments, etc.) are the ultimate nemesis and killer of the virus.

(A) "Antiviral biological missiles" are mainly drugs for new coronaviruses and mutant viruses, which act on respiratory and lung diseases. The drugs use redundant designs to inhibit new coronaviruses and variant viruses.

(B) "New Coronavirus Epidemic Prevention Tablets" mainly use natural purified elements and chemical structure modifications.

(D) "New Coronavirus Long-acting Oral Tablets" Chemical modification of antiviral drugs, multiple targets, etc.

(E) "New Coronavirus Inhibitors" (injections) are mainly made of chemical drug structure modification and other preparations.

The development of these drugs mainly includes: drug target screening, structure-activity relationship, chemical modification, natural purification, etc., which require a lot of work and experimentation.

Humans need to vigorously develop drugs to deal with various viruses. These drugs are very important for the prevention and treatment of viruses and respiratory infectious diseases, influenza, pneumonia, etc.

The history of human development The history of human evolution, like all living species, will always be accompanied by the survival and development of microorganisms. It is not surprising that viruses and infectious diseases are frequent and prone to occur. The key is to prevent and control them before they happen.

This strain was first discovered in India in October 2020 and was initially called a "double mutant" virus by the media. According to the announcement by the Ministry of Health of India at the end of March this year, the "India New Coronavirus Genomics Alliance" composed of 10 laboratories found in samples collected in Maharashtra that this new mutant strain carries E484Q and L452R mutations. , May lead to immune escape and increased infectivity. This mutant strain was named B.1.617 by the WHO and was named with the Greek letter δ (delta) on May 31.

Shahid Jamil, the dean of the Trivedi School of Biological Sciences at Ashoka University in India and a virologist, said in an interview with the Shillong Times of India that this mutant strain called "double mutation" is not accurate enough. B. 1.617 contains a total of 15 mutations, of which 6 occur on the spike protein, of which 3 are more critical: L452R and E484Q mutations occur on the spike protein and the human cell "Angiotensin Converting Enzyme 2 (ACE2)" receptor In the bound region, L452R improves the ability of the virus to invade cells, and E484Q helps to enhance the immune escape of the virus; the third mutation P681R can also make the virus enter the cell more effectively. (Encyclopedia website)

There are currently dozens of antiviral COVID-19 therapies under development. The large drugmakers Merck and Pfizer are the closest to the end, as expected, a pair of oral antiviral COVID-19 therapies are undergoing advanced human clinical trials.

Merck's drug candidate is called monupiravir. It was originally developed as an influenza antiviral drug several years ago. However, preclinical studies have shown that it has a good effect on SARS and MERS coronavirus.

Monupiravir is currently undergoing in-depth large-scale Phase 3 human trials. So far, the data is so promising that the US government recently pre-ordered 1.7 million courses of drugs at a cost of $1.2 billion. If everything goes according to plan, the company hopes that the drug will be authorized by the FDA for emergency use and be on the market before the end of 2021.

Pfizer's large COVID-19 antiviral drug candidate is more unique. Currently known as PF-07321332, this drug is the first oral antiviral drug to enter human clinical trials, specifically targeting SARS-CoV-2.

Variant of Concern WHO Label First Detected in World First Detected in Washington State

B.1.1.7 Alpha United Kingdom, September 2020 January 2021

B.1.351 Beta South Africa, December 2020 February 2021

P.1 Gamma Brazil, April 2020 March 2021

B.1.617.2 Delta India, October 2020 April 2021

Although this particular molecule was developed in 2020 after the emergence of the new coronavirus, a somewhat related drug called PF-00835231 has been in operation for several years, targeting the original SARS virus. However, the new drug candidate PF-07321332 is designed as a simple pill that can be taken under non-hospital conditions in the initial stages of SARS-CoV-2 infection.

"The protease inhibitor binds to a viral enzyme and prevents the virus from replicating in the cell," Pfizer said when explaining the mechanism of its new antiviral drug. "Protease inhibitors have been effective in the treatment of other viral pathogens, such as HIV and hepatitis C virus, whether used alone or in combination with other antiviral drugs. Currently marketed therapeutic drugs for viral proteases are generally not toxic Therefore, such molecules may provide well-tolerated treatments against COVID-19."

Various studies on other types of antiviral drugs are also gaining momentum. For example, the new coronavirus pneumonia "antiviral biological missile", "new coronavirus prevention tablets", "composite antiviral oral liquid", "new coronavirus long-acting oral tablets", "new coronavirus inhibitors" (injections), etc., are worthy of attention. Like all kinds of vaccines, they will play a major role in preventing and fighting epidemics.

In addition, Japanese pharmaceutical company Shionoyoshi Pharmaceutical is currently conducting a phase 1 trial of a protease inhibitor similar to SARS-CoV-2. This is called S-217622, which is another oral antiviral drug, and hopes to provide people with an easy-to-take pill in the early stages of COVID-19. At present, the research and development of vaccines and various new crown drugs is very active and urgent. Time does not wait. With the passage of time, various new crown drugs will appear on the stage one after another, bringing the gospel to the complete victory of mankind.

The COVID-19 pandemic is far from over. The Delta mutant strain has quickly become the most prominent SARS-CoV-2 strain in the world. Although our vaccine is still maintained, it is clear that we need more tools to combat this new type of coronavirus. Delta will certainly not be the last new SARS-CoV-2 variant we encountered. Therefore, it is necessary for all mankind to persevere and fight the epidemic together.

Overcome illness and meet new challenges. The new crown epidemic and various mutated viruses are very important global epidemic prevention and anti-epidemic top priorities, especially for the current period of time. Vaccine injections, research and development of new drugs, strict prevention and control, wear masks, reduce gatherings, strictly control large gatherings, prevent the spread of various viruses Masks, disinfection and sterilization, lockdown of the city, vaccinations, accounting and testing are very important, but this does not mean that humans can completely overcome the virus. In fact, many spreading and new latently transmitted infections are still unsuccessful. There are detections, such as invisible patients, asymptomatic patients, migratory latent patients, new-onset patients, etc. The struggle between humans and the virus is still very difficult and complicated, and long-term efforts and exploration are still needed, especially for medical research on the new coronavirus. The origin of the disease, the course of the disease, the virus invaded The deep-level path and the reasons for the evolution and mutation of the new coronavirus and the particularity of prevention and treatment, etc.). Therefore, human beings should be highly vigilant and must not be taken lightly. The fierce battle between humans and various viruses must not be slackened. Greater efforts are needed to successfully overcome this pandemic, fully restore the normal life of the whole society, restore the normal production and work order, restore the normal operation of society, economy and culture, and give up food due to choking. Or eager for success, will pay a high price.

———————————————————————————————————————————————— ————

References References are made to web resources, and related images are from web resources and related websites.

Who official website UN .org www.gavi.org/ispe.org

Wikipedia, "The Lancet", "English Journal of Medicine", "Nature", "Science", "Journal of the American Medical Association", etc.

Learning from history: do not flatten the curve of antiviral research!

T Bobrowski, CC Melo-Filho, D Korn, VM Alves...-Drug discovery today, 2020-

go.drugbank.com/

A critical overview of computational approaches employed for COVID-19 drug discovery

EN Muratov, R Amaro, CH Andrade, N Brown...-Chemical Society..., 2021-pubs.rsc.org

Global Research Performance on COVID 19 in Dimensions Database

J Balasubramani, M Anbalagan-2021-researchgate.net

Adoption of a contact tracing app for containing COVID-19: a health belief model approach

M Walrave, C Waeterloos...- JMIR public health and..., 2020-publichealth.jmir.org

Prophylactic Treatment Protocol Against the Severity of COVID-19 Using Melatonin

N Charaa, M Chahed, H Ghedira...-Available at SSRN..., 2020-papers.ssrn.com

　Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet

　Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany, New England Journal of Medicine

The actions of respiratory therapists facing COVID-19

Zhu Jiacheng-Respiratory Therapy, 2021-pesquisa.bvsalud.org

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, The Lancet

　Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China, JAMA, February 7

Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China, JAMA

Delta variant triggers new phase in the pandemic | Science

science.sciencemag.org›

COVID vaccines slash viral spread – but Delta is an unknown

www.nature.com ›articles

Novel coronavirus pneumonia during ophthalmic surgery management strategy and recommendations

YH HUANG, SS LI, X YAO, YR YANG, DH QIN…-jnewmed.com

Delta variant: What is happening with transmission, hospital ...

www.bmj.com

Risk of long QT syndrome in novel coronavirus COVID-19

VN Oslopov, JV Oslopova, EV Hazova…-Kazan medical…, 2020-kazanmedjournal.ru

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines ...

www.news-medical.net

First molecular-based detection of SARS-CoV-2 virus in the field-collected houseflies

A Soltani, M Jamalidoust, A Hosseinpour, M Vahedi...-Scientific Reports, 2021-nature.com

Covid 19 DELTA Variant Archives-Online essay writing service

sourceessay.com ›tag› covid-19-delta-variant

SARS-CoV-2 Delta variant Likely to become dominant in the ...

www.news-medical.net

Compilation postscript

Once Fang Ruida's research literature on the new crown virus and mutant virus was published, it has been enthusiastically praised by readers and netizens in dozens of countries around the world, and has proposed some amendments and suggestions. Hope to publish a multilingual version of the book as an emergency To meet the needs of many readers around the world, in the face of the new crown epidemic and the prevention and treatment of various mutant viruses, including the general public, college and middle school students, medical workers, medical colleagues and so on. According to the English original manuscript, it will be re-compiled and published. Inconsistencies will be revised separately. Thank you very much.

Jacques Lucy, Geneva, Switzerland, August 2021

*********************************************************************

Leader mondial, scientifique, scientifique médical, virologue, pharmacien et professeur Fangruida (F.D Smith) sur l'épidémie mondiale et l'ennemi juré et la prévention des nouveaux coronavirus et virus mutants (Jacques Lucy 2021v1.5)

_-----------------------------------------

L'ennemi juré et le tueur du nouveau coronavirus et des virus mutés - Développement conjoint de vaccins et de médicaments (Fangruida) Juillet 2021

* La particularité des nouveaux coronavirus et des virus mutants * Le large spectre, la haute efficacité, la redondance et la sécurité de la conception et du développement du nouveau vaccin contre le coronavirus, Redondance et sécurité

* Nouvelle modification de la structure chimique des médicaments contre les coronavirus * Conception et dépistage des médicaments assistés par ordinateur. *"Missile biologique antiviral", "Nouveaux comprimés anti-épidémiques contre le coronavirus", "Liquide oral antiviral composite", "Nouveaux comprimés oraux à action prolongée contre le coronavirus", "Nouveaux inhibiteurs de coronavirus" (injection)

——————————————————————————

(leader mondial, scientifique, scientifique médical, biologiste, virologue, pharmacien, FD Smith) "The Nemesis and Killer of New Coronavirus and Mutated Viruses-The Joint Development of Vaccines and Drugs" est un important document de recherche scientifique. Il a maintenant été révisé et réédité par l'auteur original à plusieurs reprises. La compilation est publiée et publiée selon le manuscrit original pour répondre aux besoins des lecteurs et des internautes du monde entier. En même temps, elle est également très bénéfique pour le grand nombre de chercheurs en médicaments cliniques médicaux et de divers experts et universitaires. Nous espérons qu'il sera corrigé dans la réimpression.------Compilé par Jacques Lucy à Genève, août 2021

-------------------------------------------------- ---------------------

Selon les statistiques en temps réel de Worldometer, vers 6h30 le 23 juillet, il y avait un total de 193 323 815 cas confirmés de nouvelle pneumonie coronarienne dans le monde, et un total de 4 150 213 décès. Il y a eu 570 902 nouveaux cas confirmés et 8 766 nouveaux décès dans le monde en une seule journée. Les données montrent que les États-Unis, le Brésil, le Royaume-Uni, l'Inde et l'Indonésie sont les cinq pays avec le plus grand nombre de nouveaux cas confirmés, et l'Indonésie, le Brésil, la Russie, l'Afrique du Sud et l'Inde sont les cinq pays avec le plus grand nombre de nouveaux décès.

Les nouvelles souches de coronavirus et de mutants delta ont été particulièrement graves ces derniers temps. De nombreux pays et lieux ont repris vie et le nombre de cas n'a pas diminué, mais a augmenté.

, Il est digne de vigilance. Bien que de nombreux pays aient renforcé la prévention et le contrôle des vaccins et d'autres mesures de prévention et de contrôle, il existe encore de nombreuses lacunes et carences dans la suppression et la prévention du virus. Le nouveau coronavirus et diverses souches mutantes présentent un certain degré d'antagonisme par rapport aux médicaments traditionnels et à la plupart des vaccins. Bien que la plupart des vaccins aient de grandes propriétés anti-épidémiques et aient des effets et une protection importants et irremplaçables pour la prévention et le traitement, il est impossible d'empêcher complètement la propagation et l'infection des virus. La propagation de la nouvelle pneumonie à virus couronne a été retardée de près de deux ans. Il y a des centaines de millions de personnes infectées dans le monde, des millions de décès, et le temps est long, la propagation est généralisée et des milliards de personnes dans le monde sont parmi Les dommages causés par le virus sont assez terribles, c'est bien connu. Plus urgent

Ce qui est plus grave, c'est que le virus et les souches mutantes n'ont pas complètement reculé, surtout que de nombreuses personnes sont encore infectées et infectées après avoir été injectées avec divers vaccins.L'efficacité du vaccin et la résistance du virus mutant sont dignes des scientifiques médicaux, virologues , les pharmacologues Les zoologistes et autres réfléchissent et analysent sérieusement. La situation épidémique actuelle dans les pays européens et américains, la Chine, le Brésil, l'Inde, les États-Unis, la Russie et d'autres pays s'est considérablement améliorée par rapport à l'année dernière.Cependant, les chiffres pertinents montrent que la situation épidémique mondiale ne s'est pas complètement améliorée, et certains pays et régions sont encore très graves. En particulier, après une utilisation intensive de divers vaccins, des cas surviennent encore, et dans certains endroits ils sont encore très graves, ce qui mérite une grande vigilance. Les mesures de prévention et de contrôle sont très importantes.De plus, les vaccins et divers médicaments antiépidémiques sont les premiers choix nécessaires, et les autres méthodes sont irremplaçables. Il est particulièrement important de développer et de développer des médicaments complets, des médicaments antiviraux, des médicaments immunitaires et des médicaments génétiques. Les expériences de recherche sur les nouveaux coronavirus et virus mutants nécessitent une analyse plus rigoureuse et approfondie des données, des tissus pathogènes pathologiques, des gènes cellulaires, de la chimie moléculaire, de la chimie quantique, etc., ainsi que de la chimie moléculaire des vaccins, de la physique quantique, de la biologie quantique, de l'histologie cytologique, la chimie médicinale et les médicaments Et les symptômes, l'efficacité, la sécurité, l'efficacité à long terme, etc. du vaccin, bien sûr, y compris des dizaines de milliers de cas cliniques et de décès et d'autres informations et preuves de première main. La tâche de l'ARN (acide ribonucléique) dans le corps humain est d'utiliser les informations de notre matériel génétique ADN pour produire des protéines. Il accomplit cette tâche dans le ribosome, la zone productrice de protéines de la cellule. Le ribosome est le lieu où se produit la biosynthèse des protéines.

La médecine en profite : dans la vaccination, l'ARNm produit artificiellement fournit aux ribosomes des instructions pour construire des antigènes pathogènes contre lesquels lutter, par exemple, la protéine de pointe du coronavirus.

Les vaccins vivants traditionnels ou les vaccins inactivés contiennent des antigènes qui provoquent la réaction du système immunitaire. Le vaccin à ARNm est produit dans la cellule

(1) La spécificité des nouveaux coronavirus et virus mutants, etc., virologie et chimie quantique des virus mutants, physique quantique, microbiologie quantique

(2) Nouvelle conception de vaccin couronne, biologie moléculaire et structure chimique, etc.

(3) La généralité et la particularité du développement de nouveaux médicaments contre le coronavirus

(4) Diverses conceptions de médicaments pour la pneumonie à nouveau coronavirus, la chimie médicinale, la pharmacologie, etc., les cellules, les protéines, l'ADN, la chimie des enzymes, la chimie quantique pharmaceutique, la physique quantique pharmaceutique, la biochimie humaine, la biophysique humaine, etc.

(5) Les caractéristiques d'évolution et de mutation du nouveau coronavirus et de divers virus mutants, la nature à long terme, la répétabilité, la résistance aux médicaments et la résistance épidémique du virus, etc.

(6) Pneumonie à nouveau coronavirus et transmission infectieuse de divers nouveaux coronavirus et leurs particularités

(7) La transmission invisible de la pneumonie à nouveau coronavirus et de divers virus mutants chez l'homme ou l'animal, et la symbiose mutuelle de l'infection croisée de diverses bactéries et virus sont également l'une des causes très graves de dommages graves aux nouveaux coronavirus et virus mutants. La virologie, la pathologie, l'étiologie, le séquençage des gènes, la cartographie des gènes et un grand nombre d'études analytiques ont montré qu'il existe de nombreux cas en Chine, aux États-Unis, en Inde, en Russie, au Brésil et dans d'autres pays.

(8) Pour la prévention et le traitement symptomatiques du nouveau coronavirus, la combinaison de divers vaccins et de di

statistics by Maribel de la Torre

july 2, 2005. the troubadour. los angeles, ca.

USA of Awesome Map by Joe Wolf

Highly subjective but kind of fun. Courtesy of Andrew Sullivan's blog "The Daily Dish".

Statistics - Industry by Museums of History NSW - State Archives Collection

Diagram showing area under cultivation in NSW in ten Year intervals between 1870 & 1909

Dated: by 11/05/1908

Digital ID: 14086_a005_a005SZ847000034r

Rights: www.records.nsw.gov.au/about-us/rights-and-permissions

We'd love to hear from you if you use our photos.

Many other photos in our collection are available to view and browse on our website using Photo Investigator.

STATISTICS by Jacques Rollet

Meditation: Use by U.S. Children by NIH Image Gallery

Statistics from the 2017 National Health Interview Survey show increases in U.S. adults’ use of yoga and meditation: nccih.nih.gov/research/statistics/NHIS/2017

Credit: National Center for Complementary and Integrative Health, NIH

Flickr statistics on my photostream by Rosario Sanguedolce

100,432 people from all over the world looked at my photostream until to day. Thank you very much for your lovely attention my photos: it is a great honour for me!!

statistics by Maribel de la Torre

july 2, 2005. the troubadour. los angeles, ca.

statistics and probability by Eiahi Kowalski

1 3

Eiahi Kowalski |statistics and probability | Image Source: cambridge.org | 4/29/2015

This image is taken from United States Naval Medical Bulletin Vol. 6, Nos. 1-4, 1912 by Medical Heritage Library, Inc.

Go to the Book with image in the Internet Archive

Title: United States Naval Medical Bulletin Vol. 6, Nos. 1-4, 1912

Creator: U.S. Navy. Bureau of Medicine and Surgery

Publisher:

Sponsor:

Contributor:

Date: 1912

Language: eng

Table of Contents

Number 1

Preface v

Special articles:

The medical man and vital statistics, by J. D. Gatewood 1

A plea for more liberal nomenclature for the Naval Medical Service, by A.

W. Dunbar 22

Acid fast bacilli in the circulating blood of lepers, by G. B. Crow 26

The tenth convention of the second Hague conference of 1907, and its

relation to the evacuation of the wounded in naval warfare, by F. L. Pleadwell (second

paper) 34

A study of 3,268 venereal prophylactic treatments, by R. C. Holcomb and

D. C. Gather 52

A year's experience in venereal prophylaxis on board the U. S. S.

Georgia, July 1, 1910-June 30, 1911, by C. L. Moran 60

The recent advances in the prophylaxis and treatment of typhoid fever, by

M. W. Baker 62

United States Medical School laboratories:

The Naval Medical School collections, by P. E. Garrison 69

Additions to the helminthological collection, United States Naval

Medical School, September-November, 1911 72

Additions to the pathological collection, United States Naval Medical School,

September-November, 1911 72

Suggested devices:

Modification in shoe for prevention of blisters on the heel, by W. S.

Sims. . 73

An improved cot for hospital ships and sick bays aboard ship, by E. M. Blackwell

73

Clinical notes:

Umbilical hernia, by H. F. Strine 76

Report of a case resembling gangosa in which treponema pertenuis was present,

by P. S. Rossiter 78

Bunion operations, by A. M. Fauntleroy 79

Late positive Wassermann in syphilis and tuberculosis, by W. B. Grove.

... 81

Salvarsan in frambcesia, by G. F. Cottle 82

Salvarsan in filariasis, by G. F. Cottle 84

Current comment:

The twentieth annual meeting of the Association of Military Surgeons.

... 89

The ninth international Red Cross conference 90

Typhoid fever 91

Yellow fever at Honolulu 92

Opening of the Naval Hospital, Great Lakes training station, 92

Progress in medical sciences:

General medicine. —Pulmonary tuberculosis, experiences with, during

last year; possible infectious origin of pernicious anemia; differential diagnosis

in albuminuria; observations on urine of marathon runners; alcohol in dermal

therapeutics; baldness and its cures; relationship of syphilis and

tuberculosis; present status of salvarsan therapeutics; effect of salvarsan upon

the heart; utilization of Wassermann reaction in the Navy; possible specific

treatment of diabetes mellitus; bromidrosis and hyperidrosis

of the feet; by A. W. Dunbar and J. L. Neilson 93

Surgery. —Open treatment of transverse fracture of femoral shaft; cure

of prostatic obstruction; organization at main battle dressing station; by R.

Spear 107

Hygiene and sanitation. — A strength and endurance test; dangers to

health from automobile engine gases; decomposing power of bacteria in water; epidemic

due to Gartner bacillus; bacteriological investigation of ice cream in Boston;

emergency rations; accidents of decompression; merits of low protein diet;

concerning particles of albuminous substance in exhaled air; influence of

storage and preservatives upon dissolved oxygen in waters; bacteriological

examinations of oysters; by H. G.

Beyer and C.N. Fiske 113

Tropical medicine. — Preliminary report on method of preventing pernicious

malaria; recent advances in knowledge of sleeping sickness; experiments on the

cause of beriberi; action of quinine, salvarsan and atoxyl on Plasmodium

prrecox in canary birds; relationship between Gl. Morsitans and sleeping

sickness; by E. R. Stitt 124

Pathology and bacteriology. —Detection of tubercle bacilli in sputum; method

of infection in pneumonic plague; study of arteritis of syphilitic origin;

isolation of typhoid, paratyphoid and dysentery bacilli; bacteriological

examination of stools in quarantine protection against cholera; local

production of antibodies; by M. E. Higgins 130

Medical zoology.—Etiology of pellagra, by P. E. Garrison 136

Chemistry and pharmacy. —Determination of arsenic in urine after administering

salvarsan; method for detection of salvarsan; method for estimation of gastric

acidity; absorption of chloroform and other chlorinated hydrocarbons by men and

animals; by E. W. Brown and O. G. Ruge... 136

Eye, ear, nose, and throat. —Acute nephritis following acute tonsillitis;

when to remove tonsils and what operation to be used; recent contributions to

knowledge of sympathetic ophthalmia; protest against indiscriminate use of

organic compounds of silver in ophthalmic practice; two cases of iritis treated

with salvarsan ; a quick and easy method for removal of eyeball; by E. M. Shipp

138

Reports and letters:

Sanitary report on Hampton Roads, Norfolk, and vicinity, by G. A. Lung.

149

Recent pellagra clinic at Columbia, S. C, by P. E. Garrison 152

A visit to the Finsen Institute, by R. B. Williams 157

Number 2

Preface vi

Special articles:

Lead poisoning from inhalation of red-lead laden dust. The possible frequency

of lead encephalopathy in such cases, by E. R. Stitt 161

Loss of life by drowning in naval warfare, by T. W. Richards 166

Etiology of gangosa, based upon complement fixation, by E. P. Halton. .

. 190

Further observations on the insane of the Navy, by Heber Butts 193

Roaches and their extermination by the use of sodium fluorid, by M. F. Gates

212

The prophylaxis of boils, by E. W. Phillips 214

Extract from sanitary report, U. S. S. Washington, by J. H. Iden 215

Comment, by J. D. Gatewood 216

Damage table for physical disability in the United States Navy, 1910. International

nomenclature, by C. N. Fiske 217

Indications for intubation and tracheotomy, by G. B. Trible 219

Report on methods of administration of and results obtained from

"salvarsan." Based upon the treatment of over 200 cases of syphilis

at the naval hospital, Mare Island, Cal., by J. A. Biello 221

Method used at naval hospital, Chelsea, Mass., by F. M. Furlong 225

Method used at naval hospital, Norfolk, Va., by W. M. Garton 225

Method used at naval hospital, New York, N. Y., by C. M. Oman 226

Distribution of tubercle bacilli in the sputa of tuberculous patients,

by R. W. King 227

United States Naval Medical School laboratories:

Specimens added to the helminthological collection, December, 1911-February,

1912 229

Specimens added to the pathological collection, December,

1911-February, 1912 231

Miscellaneous collection, December, 1911-February, 1912 231

Suggested devices:

An incubator for gelatine cultures, by F. L. Letts 233

Clinical notes:

Report of a case of perforation of the sigmoid by an ulcer, in a case

of dysentery (Flexner-Strong), by Raymond Spear and M. E. Higgins 235

Plastic operation of lip, by R. A. Bachmann 236

Removal of entire fibula, by J. L. Neilson 236

Frontal sinusitis, followed by double mastoiditis; operations, by G. B.

Trible 239

"Salvarsan " in syphilis, leprosy, and yaws, by W. M. Kerr

240

Two surgical cases occurring on the U. S. S. South Carolina, by R. B. Williams

242

1. Abscess of prostate, gangrene of scrotum, pyemia, death.

2. Tonsillitis; tonsillectomy, acute nephritis, uremia.

Surgical cases from the naval hospital, Norfolk, Va., by H. F. Strine

243

1. Lacerated kidney, nephrectomy.

2. Gastro-enterostomy.

3. Cholecystocolostomy; external biliary fistula; stricture of common duct.

4. Multiple abscess of liver.

Editorial comment:

Yellow fever on the Yorktown, by C. F. Stokes 249

The Naval Medical Bulletin 260

Hospital ships 250

Paresis and "line of duty " 253

Progress in medical sciences:

General medicine. — Relation of so-called Brill's disease to typhus

fever. Diagnostic importance of hemoptysis. Acute dilatation of the stomach in

pneumonia. Reaction induced by antityphoid vaccination, by A. W. Dunbar and J.

L. Neilfon 255

Surgery. —Organization of the medical service at the main dressing

station in battle, by H. G. Beyer. The error of overlooking ureteral or renal stones

under the diagnosis of appendicitis. The incision for lumbar

exposure of the kidney. Iodine as the sole dressing for operation

wounds. A review of recent methods for the radical cure of hernia. Studies in peritoneal

adhesions. The surgical treatment of colitis, by Raymond Spear and C. M. Oman

259

Hygiene and sanitation. —A symposium on the effects of athletics on

young men, by J. L. Neilson. Mosquito larvicides, by E. R. Stitt. Sur une cause

possible du gout empyreumatique de l'eau de boisson a bord des navires de

guerre, by C. L. Moran. Organic matter in expired air. Tests for freshness of

milk, by E. W. Brown. Experiments in book disinfection. The purification of

water by anhydrous chlorine. Oral hygiene (preliminary contribution on the care

of the mouth). On the survival of specific microorganisms in pupae and imagines

of musca domestica raised from experimentally infected larvae : Experiments

with B. typhosus. On the varieties of B. coli associated with the house fly, by

C. N. Fiske. 271

Tropical medicine. —A few words on the distribution of smallpox,

tuberculosis, and typhoid in the tropics. Do mosquitoes require blood as

nourishment in the development of their eggs? By E. R. Stitt 279

Pathology and bacteriology. —An attempt to differentiate the

diphtheroid group of organisms. The period of infectivity of the blood of

measles; an experimental demonstration of the presence of the virus of measles

in the mixed buccal and nasal secretions; the nature of the virus of measles; the

infectivity of the secretions and disquamating scales of measles. A new

conception of immunity. Complement in human serum, by M. E. Higgins 281

Medical zoology. —A comparative study of the ameba in the Manila water supply,

in the intestinal tract of healthy persons and in amebic dysentery. The Rocky

Mountain spotted fever tick, with special reference to the problems of its

control in Bitter Root Valley, Montana, by P. B. Garrison 283

Chemistry and pharmacy. —Some considerations on the absorption and excretion

of drugs. Detection of albumoses in urine. Estimation of free HC1 in gastric

contents by capillary method. Detection of albumin in urine by Merck's tablets.

Estimation of acetone in animal liquids. New test for bile in urine. Method for

determining formaldehyde. Indirect method for determining total volume of

gastric contents, by E. W. Brown and O. G. Ruge 286

Eye, ear, nose, and throat.—Abscess of the nasal septum. Observations upon

the treatment of gonorrheal conjunctivitis in the adult, by E. M. Shipp 291

Reports and letters:

Yellow fever occurring on board the U. S. S. Yorktown at Guayaquil, Ecuador,

extracts from a report on cases of, by C. B. Camerer 295

Report on military surgery at Foochow, China, by J. G. Omelvena 300

Notes on Camp Meyer, Guantanamo Bay, Cuba, by L. W. Johnson 303

Special report on the general surgical department, Naval Hospital,

Norfolk, Va. Anesthesia. Prophylaxis of wound infection. Appendicitis. Post-operative

treatment, by H. F. Strine 305

American Public Health Association meeting (abstract of report on), by W.

H. Short 309

Number 3

Preface v

Special articles:

Leprosy, with notes on, and illustrations of the cases as they occurred

in the Tumon Leper Colony, Guam, Marianas, during the months of October and

November, 1911, by W. M. Kerr, assistant surgeon, United States Navy 313

Photographs of lepers, by G. F. Cottle, passed assistant surgeon,

United States Navy 342

Vision in relation to marksmanship, by E. J. Grow, surgeon, United States

Navy 344

Technique of a Wassermann test in which guinea-pig complement is not required;

Emery technique; Noguchi reagents, by E. R. Stitt, medical inspector, United

States Navy 362

Some minor sanitary defects in modern battleships, and their correction,

by F. L. Pleadwell, surgeon, United States Navy 309

Additional report of cases with unusual symptoms caused by contact with

some unknown variety of jelly fish, by E. H. Old, passed assistant surgeon,

United States Navy 377

The effects of high temperature on the personnel of the fire rooms of

naval vessels with special reference to heat cramps (myalgia thermica), by W.

L. Mann, passed assistant surgeon, United States Navy 380

Detection of methyl alcohol, by C. Schaffer, hospital steward, United States

Navy 392

United States Naval Medical School laboratories:

Additions to the helminthological collection 395

Additions to the pathological collection 395

Additions to the miscellaneous collection 396

Suggested devices:

A bunk locker, a tray, and a bracket stool for use in sick bays and

wards of hospital ships, by E. M. Blackwell, surgeon, United States Navy 397

A method for use in opsonic index work and vaccine standardization, by R.

E. Weaver, hospital steward, United States Navy 398

Clinical notes:

A note on a case of fish poisoning in Guam, by W. M. Kerr, assistant

surgeon, United States Navy 401

Two cases of climatic bubo, by E. W. Phillips, assistant surgeon,

United States Navy 402

Rupture of the left kidney (nephrectomy), by A. M. Fauntleroy, surgeon,

United States Navy 404

Abscess of the liver in a young infant, by F. E. Sellers, passed

assistant surgeon, United States Navy 405

Appendectomy on a haemophiliac, by B. F. Jenness, passed assistant surgeon.

United States Navy 407

Editorial comment:

New accounting system at naval hospitals, by Surg. Gen. C. F. Stokes, United

States Navy 411

The relations of the American National Red Cross with the Medical

Department of the Navy in war 413

Progress in medical sciences:

General medicine. — Physical exercise and blood pressure. On the

identity of typhus fever and Brill's disease. Studies on the virus of typhus,

by A. W. Dunbar and J. L. Neilson 417

Surgery.— The prevention and treatment of ventral hernia. Technique and

remote results of vascular anastomoses. Accidents and deaths from exploratory

puncture of the pleura. The control of bleeding in brain operations. Surgical

pathology of the stomach and duodenum, by R. Spear and C. M. Oman 421

Hygiene and sanitation.— The physiological influence of ozone.

Influence of benzine, toluene, and light and heavy "benzines" on the

organism, by E. W. Brown. Disinfection experiments with perautan and paragan. A

new and rapid method of bacteriological water examination, its applicability to

the testing of filtered and well water. A mosquito larvacide disinfectant and

the methods of its standardization. The sterilization of milk bottles with

calcium hypochlorite. Apyrexial malaria carriers, by H. G. Beyer and O. N.

Kiske 431

Tropical medicine. — Cell-inclusions in the blood of a case of

blackwater fever. The estimation of the specific gravity of the blood and its

value in the treatment of cholera, by E. R. Stitt 436

Pathology and bacteriology.— A study of 35 strains of streptococci

isolated from samples of milk, by C. N. Fiske. Method for the quantitative determination

of fecal bacteria, by E. W. Brown. Pure cultivation of

spirochieta refringens, by M. E. Higgins 438

Chemistry and pharmacy. —On the diagnostic value of colloidal nitrogen

in the urine in cases of carcinoma. Determination of the quantity of residual

urine. Clarification of the urine in the estimation of sugar. On the excretion

of formaldehyde, ammonia, and hexamethylenamine. Organic compounds of the

aromatic series as cholagogucs, by E. W. Brown and O. G. Ruge 439

Eye, ear, nose, and throat. — An operation for glaucoma. Notes from an Indian

eye clinic. In the report from the St. Louis Ophthalmological Society in a

discussion on the antiseptic and germicidal properties of the silver salts.

Notes of three cases illustrating infection of the accessory sinuses by entry

of water into the nose during bathing. Three cases of chronic suppurative

otitis media, by G. B. Trible 441

Reports and letters:

An account of the sinking of the Japanese battleship Hatsuse in the

late Russo-Japanese war, by F. L. Pleadwell, surgeon, United States Navy.. 447

Organization, camp management, and sanitation in effect at the marine barracks,

Camp Elliott, Isthmus Canal Zone, Panama, April 15, 1910, to February 26, 1912,

by S. D. Butler, major, United States Marine Corps.. 458

Sanitary conditions in Samoa, by R. U. Reed, passed assistant surgeon, United

States Navy 462

Sanitary conditions in Guam, by C. P. Kindleberger, surgeon, United

States Navy 464

Number 4

Preface v

Special articles

A description of recent hospital construction in the United States

Navy, by A. W. Dunbar, surgeon, United States Navy 473

A few general principles of hospital construction, by F. W. Southworth,

S. B., architect 523

Ventilation of warships, by R. H. Robinson, naval constructor, United States

Navy 529

Plans and description of a hospital ship for the United States Navy, by

E. M. Blackwell, surgeon, United States Navy 539

A report on the prevalence of framboesia (yaws) in Guam, and its

connection with the etiology of gangosa, by W. M. Kerr, assistant surgeon,

United States Navy 549

Diagnosis and dosage in hookworm cases in the Navy, by J. F. Leys,

surgeon, United States Navy 552

Nitrous oxide-oxygen anesthesia, by H. F. Strine, surgeon, United

States Navy 555

A theoretical discussion of the character and genesis of thermic

myospasms, with further observations on myalgia thermica, by W. L. Mann, passed

assistant surgeon. United States Navy 558

Eight hundred and twenty complement-fixation tests on 461 patients, by E.

P. Huff, passed assistant surgeon. United States Navy 562

United States Naval Medical School laboratories:

Additions to the helminthological collection 575

Additions to the pathological collection 575

Additions to the miscellaneous collection 575

Suggested devices:

A simple method of securing shelf-bottle stoppers during target

practice, by H. S. Coombs, hospital apprentice, first class. United States

Navy. . . . 577

The rat guard used in the Philippine Islands, by C. Fox, passed assistant

surgeon, United States Public Health Service 577

Clinical notes:

Case reports from the United States naval hospital, Philadelphia, by G.

B. Crow, L. W. Johnson, A. J. Toulon, and C. W. Smith, passed assistant surgeons,

United States Navy 579

A case of very large stone in kidney without acute symptoms.

Pneumonia following an injury.

The effect of salvarsan on the average number of sick days from

syphilis.

A case of extensive adenocarcinoma.

A case of exceptionally severe syphilitic Irido-cyclltis with marked

changes in the interior of the eye and total loss of light perception.

An interesting case of gunshot wound, by J. M. Minter, passed assistant

surgeon, United States Navy 584

Fracture of humerus by muscular action, by R. G . Davis, assistant

surgeon, United States Navy 585

Editorial comment :

Participation of Medical Officers in Professional Conferences 587

Sight tests for seamen 588

Recent legislation affecting the Medical Department of the Navy 589

Naval Hospital Corps 590

Progress in medical sciences:

General medicine. —Bier's hypersemic treatment in gonorrhceal epididymitis,

by C. N . Fiske. Normal human blood serum in obstetric practice. The cutaneous

reaction of syphilis. Clinical experience with neosalvarsan. By A. W. Dunbar

and J. L. Neilson 591

Surgery. — Local anesthesia in traumatic surgery. Surgery of the bile

ducts. Vanadium steel bone plates and screws. Observations on the diagnosis of

renal tuberculosis, the indications for nephrectomy in its treatment, and the

technic of the operation. Pyloroplasty. By R. Spear and C. M. Oman 596

Hygiene and sanitation. —Notes on the ventilation of troopships in the Tropics.

The structure and functions of the foot. By H. G. Beyer and C. N. Fiske 608

Tropical medicine. — The antineuritic bases of vegetable origin in

relation to beriberi, with a method of isolation of torulin, the antineuritic

base of yeast, by J. L. Neilson 609

Pathology and bacteriology. —Double-stain method for the polar bodies

of diphtheria bacilli, by O. G. Huge. The examination of diphtheria specimens;

a new technique in staining with toluidin blue. A critical

study of the organisms cultivated from the lesions of human leprosy,

with a consideration of their etiological significance. By M. E. Higgins 611

Medical zoology. — Trypanosoma rhodesiense, a second species of

trypanosome producing sleeping sickness in man, by J. L. Neilson 612

Chemistry and pharmacy.— Studies in bacterial metabolism, by C. N. Fiske.

The definition of normal urine. The estimation of indican in urine. A new

method for the determination of total nitrogen in urine.

On the determination of ammonia in urine. By E. W. Brown and O. G. Ruge

613

Eye, ear, nose, and throat. —Tonsillectomy with consideration of its

complications. Protargol in antisepsis of the visual apparatus. The trachoma

question. Keratitis as a cause of myopia. By G. B. Trible 617

Reports and letters:

Fourth Provisional Regiment, United States Marines, Camp Thomas, North

Island, San Diego, Cal., by R. E. Hoyt, passed assistant surgeon, United States

Navy 623

Marine Expeditionary Force, Pekin, China, by R. B. Henry, assistant surgeon,

United States Navy 632

If you have questions concerning reproductions, please contact the Contributing Library.

Note: The colors, contrast and appearance of these illustrations are unlikely to be true to life. They are derived from scanned images that have been enhanced for machine interpretation and have been altered from their originals.

Read/Download from the Internet Archive

See all images from this book

See all MHL images published in the same year

Thanks! by Skip Moore

3 7

200,000 views. Wow. It might arrive via a roller coaster, but I'm really appreciative of each and everyone that has visited my photostream to have a look at my visions.

MN graduation rate data by Tim Wilson

Presented by MN State Economist Tom Stinson and MN State Demographer Tom Gillaspy at the AMSD state conference Jan. 19, 2011.

001-For the love of figures by Trevor Butcher

2 8

I ran into a feminist who refused to publish my comment on her blog item on a UK feminist blog group because she refused to accept it based on it not being evidence. OK, I thought, sounds fair enough, but I probed further and discovered she wasn't a feminist at all, she was a hierarchy climber who loved statistics to the point it blinded her to the values of loving her fellow human beings. She is of the type common in government offices - can give you no end of suggestions but if you don't fit her model you will be excluded.

I also read somewhere that art works best when the distance between art and experience is as short as possible. Well, I have outlined my experience, here is my art :)